文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

非小细胞肺癌的免疫治疗抵抗：从机制到临床策略。

Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies.

机构信息

Key Laboratory of Radiation Oncology of Taizhou, Radiation Oncology Institute of Enze Medical Health Academy, Department of Radiation Oncology, Taizhou Hospital Affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.

Department of Radiation Oncology, Xi'an No. 3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, Shaanxi, China.

出版信息

Front Immunol. 2023 Apr 6;14:1129465. doi: 10.3389/fimmu.2023.1129465. eCollection 2023.

DOI:10.3389/fimmu.2023.1129465
PMID:37090727
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10115980/
Abstract

The high primary resistance incidence and unavoidable secondary resistance are the major clinical obstacle to lasting long-term benefits in Non-small-cell lung cancer (NSCLC) patients treated with immunotherapy. The mechanisms of immunotherapy resistance in NSCLC are complex, mainly involving tumor cells and tumor microenvironment (TME) infiltrating immune cells, including TAMs, B cells, NK cells, and T cells. The selection of clinical strategies for NSCLC progression after immunotherapy resistance should depend on the progressive mode. The progression pattern of NSCLC patients after immunotherapy resistance can be divided into oligo-progression and systemic/multiple progression, which should be considered for further treatment selection. In the future, it needs to explore how to optimize the combined therapy and explore strategies to reprogram infiltrating immune cells under various genetic backgrounds of tumor cells and timely reshape TME during antitumor treatments.

摘要

免疫治疗在非小细胞肺癌（NSCLC）患者中的长期获益面临的主要临床障碍是高原发性耐药发生率和不可避免的继发性耐药。NSCLC 免疫治疗耐药的机制复杂，主要涉及肿瘤细胞和肿瘤微环境（TME）浸润免疫细胞，包括 TAMs、B 细胞、NK 细胞和 T 细胞。免疫治疗耐药后 NSCLC 进展的临床策略选择应取决于进展模式。免疫治疗耐药后 NSCLC 患者的进展模式可分为寡进展和系统性/多发性进展，应考虑进一步治疗选择。未来需要探索如何优化联合治疗，并探索在肿瘤细胞各种遗传背景下重编程浸润免疫细胞的策略，以及在抗肿瘤治疗过程中及时重塑 TME。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/10115980/fb1067440722/fimmu-14-1129465-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/10115980/39dd2ee1546a/fimmu-14-1129465-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/10115980/d0b8808c6fbb/fimmu-14-1129465-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/10115980/2e7b30f85b22/fimmu-14-1129465-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/10115980/18729b10bbd8/fimmu-14-1129465-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/10115980/fb1067440722/fimmu-14-1129465-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/10115980/39dd2ee1546a/fimmu-14-1129465-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/10115980/d0b8808c6fbb/fimmu-14-1129465-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/10115980/2e7b30f85b22/fimmu-14-1129465-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/10115980/18729b10bbd8/fimmu-14-1129465-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/10115980/fb1067440722/fimmu-14-1129465-g005.jpg

相似文献

[1]
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies.

Front Immunol. 2023

[2]
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.

J Immunother Cancer. 2022-7

[3]
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.

Cancer Biol Med. 2020-8-15

[4]
VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment.

Int J Biol Sci. 2022

[5]
Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer.

Thorac Cancer. 2022-4

[6]
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.

Theranostics. 2021

[7]
Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.

Front Immunol. 2022

[8]
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.

Cancer Treat Rev. 2020-7-7

[9]
[Advances of Immunotherapy Resistance and Coping Strategies 
in Non-small Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi. 2023-1-20

[10]
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer.

J Immunother Cancer. 2023-7

引用本文的文献

[1]
Mesenchymal Stem Cell-Conditioned Media-Derived Exosomes Loaded With Extract Inhibit Lung Cancer via NF-κB and MAPK Pathway Modulation.

Food Sci Nutr. 2025-8-20

[2]
Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancer.

Front Immunol. 2025-7-31

[3]
Aggressive Progression of High Programmed Death-Ligand 1 (PD-L1) Non-small Cell Lung Cancer Presenting as Life-Threatening Esophageal Obstruction: A Case of Food Impaction Secondary to Subcarinal Lymph Node Compression.

Cureus. 2025-6-26

[4]
Research progress of anti-angiogenic therapy combined with immunotherapy and radiotherapy for the treatment of brain metastases in non-small cell lung cancer (Review).

Oncol Lett. 2025-7-8

[5]
Treatments and Outcomes After Platinum-Based Chemotherapy and Anti-PD-(L)1 in NSCLC.

JAMA Netw Open. 2025-6-2

[6]
The complex interplay of TROP2 and PD-L1 in immune regulation and drug resistance in lung cancer.

Am J Cancer Res. 2025-5-25

[7]
Curcumin inhibits IFN-γ induced PD-L1 expression via reduction of STAT1 Phosphorylation in A549 non-small cell lung cancer cells.

Saudi Pharm J. 2025-6-5

[8]
Exceptional Long-term Response to Immunotherapy in an African American Man With -Mutated Metastatic Lung Adenocarcinoma.

J Investig Med High Impact Case Rep. 2025

[9]
Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC.

J Immunother Cancer. 2025-5-22

[10]
Resistance in Lung Cancer Immunotherapy and How to Overcome It: Insights from the Genetics Perspective and Combination Therapies Approach.

Cells. 2025-4-12

本文引用的文献

[1]
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.

Cancer. 2023-1-15

[2]
Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies.

Front Pharmacol. 2022-8-10

[3]
Cabozantinib for the treatment of solid tumors: a systematic review.

Ther Adv Med Oncol. 2022-7-13

[4]
Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody.

J Immunother Cancer. 2022-7

[5]
Emerging role of natural products in cancer immunotherapy.

Acta Pharm Sin B. 2022-3

[6]
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

N Engl J Med. 2022-5-26

[7]
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).

Lung Cancer. 2022-4

[8]
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.

Cancer Cell. 2022-3-14

[9]
Cancer statistics, 2022.

CA Cancer J Clin. 2022-1

[10]
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.

Lung Cancer. 2022-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索